Prostate Screening vs Control: Deaths From All Causes
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.179 | 0.175 | 0.183 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.185 | 0.181 | 0.189 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00608 | -0.0115 | -0.000619 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.967 | 0.939 | 0.997 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.96 | 0.925 | 0.996 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Prostate Screening than on Control | 164 | 86.7 | 1,610 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Prostate Screening | Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years. | 6,855 | 38,340 | OG001 | ClinicalTrials.gov |
| Group 2 | Control | Participants receive standard medical care. | 7,089 | 38,345 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Deaths From All Causes | ClinicalTrials.gov |
| Description | Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. | ClinicalTrials.gov |
| Time frame | Events through 13 years of follow-up or through December 31, 2009. | ClinicalTrials.gov |
| Population | All male participants were analyzed. An intention-to-treat analysis was performed. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | ClinicalTrials.gov |
| NCT number | NCT00002540 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Prostate Carcinoma | ClinicalTrials.gov |
| Interventions | Laboratory Biomarker Analysis, Medical Examination Assessment, Screening Questionnaire Administration | ClinicalTrials.gov |
| Lead sponsor | National Cancer Institute (NCI) | ClinicalTrials.gov |
| Results first posted | 2014-06-26 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00002540?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.